FibroGen (FGEN) Reports Positive Phase 3 Pooled Roxadustat Safety & Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to FibroGen (FGEN) Reports Positive Phase 3 Pooled Roxadustat Safety & Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

November 8, 2019 2:10 PM EST

Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+

Time to event endpoints using Cox model, ITT analysis* NDD (OLYMPUS, ANDES, ALPS), N=4270*ITT analysis agreed with the FDA... More